Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
SEATTLE and SOUTH SAN FRANCISCO, Calif., June 01, 2017 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies 2017 Global Healthcare Conference in New York on Wednesday, June 7, 2017 at 8 a.m. ET.
A live webcast of the presentation will be available online from the investor relations page of the company's corporate website at http://ir.immunedesign.com/events.cfm. After the live webcast, an archive of the presentation will be available on the company website for 30 days.
About Immune Design
Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the primary foci of Immune Design's ongoing immuno-oncology clinical programs, are products of its two synergistic discovery platforms, ZVex® and GLAAS®. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.
Media Contact Julie Rathbun Rathbun Communications [email protected] 206-769-9219 Investor Contact Shari Annes Annes Associates [email protected] 650-888-0902
